years and older with atrial fibrillation (AF) and renal dysfunction who are treated with apixaban. Methods: A sub analysis of a multicenter prospective cohort registry, where consecutive eligible apixaban ... subjects…
Background: The direct factor Xa (FXa) inhibitors Apixaban and Rivaroxaban are used for stroke prevention in patients with atrial fibrillation (AF). The FXa-inhibitors do not require routine laboratory monitoring…
real-life management of patients undergoing cardiac rhythm procedures and therapies while receiving apixaban. Methods: This observational, multicentre study prospectively collected data from patients with non valvular…
chromatographic method (RP-HPLC) good sensitivity was determined for the development and validation of Apixaban. In Water Apixaban λmax was fixed as 259nm using a Shimadzu UV-Visible spectrophotometer ... rate and…
administered. The High Performance Thin Layer Chromatography method was adopted for the analysis of apixaban and atorvastatin. The method validation for the individual drugs was carried out according ... human body. The…
This research compared the efficacy of apixaban and low molecular weight heparin in patients undergoing hip arthroplasty and their influence on coagulation function and postoperative deep vein thrombosis. We enrolled…
Apixaban is a new oral selective factor Xa inhibitor. Its efficacy and safety are being investigated in a large clinical development program across various indications in venous and arterial thrombotic ... disorders. A…
performed a single-center, retrospective cohort study of 98 cases of DOAC therapy (apixaban, dabigatran, or rivaroxaban) in a Veteran population with AF aged > 75 years. Baseline characteristics and comorbidities…
Apixaban (APX) is a potent oral anticoagulant drug that directly inhibit coagulation factor Xa for prevention of venous thromboembolism (VTE) following total hip or knee replacement surgery. Orally
laboratory assay are available for measuring the drug level of dabigatran, rivaroxaban and apixaban. The measurement of rivaroxaban and apixaban can be done by anti-Xa assay and dilute thrombin
Novel oral anticoagulants (NOACs), direct thrombin inhibitor (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban and edoxaban) are available in market as an alternative to warfarin. They are widely being…
patients with active GI and GU malignancies who received either enoxaparin or a DOAC (apixaban or rivaroxaban) for CAT from July 2001 to July 2020. Demographics, disease characteristics, thrombosis data ... year were…
risk of stroke and 68.4% at intermediate risk were prescribed an OAC, respectively. Apixaban was the direct oral anticoagulant of choice with 36.6% of patients prescribed an OAC receiving apixaban
used instead of warfarin due to less risk of blood clotting in patients. Apixaban, Dabigatran and Rivaroxaban are most commonly used NOACs drugs. This review article gives complete description about
summarizes the evidence that warfarin and recently developed novel oral anticoagulants (e.g., dabigatran, rivaroxaban, apixaban and tecarfarin) are effective for reducing stroke risk in AF patients. We also review
efï¬Ã‚Âcacy and safety of the new oral anticoagulants namely; dabigatran, rivaroxaban and apixaban in patients with AF. Methods: In total 286 abstracts have been screened and 21 articles
drugs, called âÂ?Â?target-specific oral anticoagulantsâÂ? (TSOACs), includes dabigatran, rivaroxaban, and apixaban. Atrial Fibrillation (AF) is a common tachy-arrhythmia in Australia, with a prevalence over ... warfarin…
each of the four targeted-specific oral anticoagulants (TSOACs), dabigatran, rivaroxaban, apixaban, and edoxaban vs. warfarin for the treatment of nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE)…
line therapies for this indication in international guidelines. The approval of dabigatran, rivaroxaban and apixaban by US and European medication authorities has resulted in widespread uptake of these agents
evaluated through a general cardiovascular clinic, could benefit from a treatment with a NOAC (apixaban, dabigatran, edoxaban and rivaroxaban) based on the data available and on the patient’s medical ... benefit from…